Hyperphosphatemia

Subscribe to Selected New Research on Hyperphosphatemia

975 relevant articles (57 outcomes, 62 trials/studies) found for this Disease

Description: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.

Also Known As:

Hyperphosphatemias

Relationship Network

Disease Context: Research Results

Nutritional and Metabolic Diseases

Metabolic Diseases: 1406

Phosphorus Metabolism Disorders: 13

Hyperphosphatemia: 975

Related Diseases

1.	Hypercalcemia (Milk Alkali Syndrome)
2.	Secondary Hyperparathyroidism
3.	Hypocalcemia
4.	Chronic Kidney Failure (Chronic Renal Failure)
5.	Hyperparathyroidism

Experts

1.	Qunibi, Wajeh Y: 4 articles (06/2005 - 07/2003)
2.	Nolan, Charles R: 4 articles (06/2005 - 07/2003)
3.	Wu, Mai-Szu: 2 articles (01/2008 - 01/2008)
4.	Algranati, L: 2 articles (01/2008 - 01/2004)
5.	Fukagawa, Masafumi: 2 articles (08/2007 - 11/2005)
6.	Shigematsu, Takashi: 2 articles (08/2005 - 08/2005)
7.	Butani, Lavjay: 2 articles (01/2005 - 04/2003)
8.	Moran, John: 1 article (09/2008)
9.	Blair, Martin: 1 article (09/2008)
10.	Wong, Amy: 1 article (09/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperphosphatemia:

1.	CalciumIBA 01/01/2009 - "Visible derangements of calcium and phosphate levels start to become apparent when GFR falls below 40 ml/min. In some but not all patients, hyperphosphatemia may be a mortality risk predictor in CKD stages 4-5. There are only few treatment studies targeting hyperphosphatemia in these CKD stages. " 02/01/2008 - "An increasing body of evidence from experimental studies and in vivo data suggest that (I) a mineral imbalance with hyperphosphatemia and high-circulating calcium x phosphate product, (II) a deficiency of systemic or local calcification inhibitors, (III) death or 'damage' of vascular smooth muscle cells (VSMCs), and/or (IV) phenotypic transformation of VSMCs to osteo/chondrocytic cells may all act in concert to initiate and sustain vascular calcification. " 02/01/2009 - "Hyperphosphatemia and calcium treatment are some of the factors associated with development of vascular calcifications, especially in the presence of low bone turnover disease. " 12/01/2008 - "Given the dramatic increase in skeletal size during growth, the need to preserve skeletal mass during adulthood, and the large capacity of bone to store calcium and phosphate, juxtaposed with the essential role of phosphate in energy metabolism and the adverse effects of hyperphosphatemia, it is not surprising that a complex systems biology has evolved that permits cross-talk between bone and other organs to adjust phosphate balance and bone mineralization in response to changing physiological requirements. " 12/01/2008 - "Hyperphosphatemia and calcium overload are associated with development of vascular calcifications, especially in the presence of low bone turnover. " Order ALL the reference details at left...
2.	sevelamer (RenaGel)FDA Link 08/01/2008 - "This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance." 07/01/2008 - "BACKGROUND: Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis. " 12/01/2007 - "Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. " 10/01/2008 - "In addition, the efficacy of sevelamer as a monotherapy in lowering phosphate to target levels in severe hyperphosphatemia remains debatable. " 05/01/2001 - "Based on the degree of hyperphosphatemia during washout, patients were started on 403 mg sevelamer capsules with a dose schedule different from previous studies. " Order ALL the reference details at left...
3.	Vitamin D FDA LinkGeneric 07/01/2007 - "Understanding the independent and context-dependent interactions between hyperphosphatemia and excessive vitamin D activity, as well as vascular calcifications and mortality in FGF23 null mice, may ultimately provide important insights into the management of clinical disorders of hyperphosphatemia and excess vitamin D activity." 07/01/2007 - "This suggests that hyperphosphatemia, rather than excessive vitamin D activity, is the major stimulus for vascular calcifications and contributes to the increased mortality in the FGF23-null mouse model. " 07/01/2007 - "For determination of the independent roles of hyperphosphatemia and excess vitamin D activity on the observed phenotypic abnormalities, FGF23 null mice were fed a phosphate- or vitamin D-deficient diet. " 08/01/2000 - "Control of hyperphosphatemia, maintenance of normocalcemia, and appropriate dosing of vitamin D analogues can prevent HPT in many cases. " 12/01/1994 - "Deficiencies of active vitamin D should be treated by oral vitamin D substitution after correction of hyperphosphatemia. " Order ALL the reference details at left...
4.	Calcium Carbonate (Limestone)FDA Link 07/01/1998 - "Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis." 09/01/1991 - "Calcium carbonate in hyperphosphatemia." 06/01/2004 - "Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients." 01/01/1999 - "[Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis]" 03/03/1990 - "[Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients]" Order ALL the reference details at left...
5.	PhosphorusIBA 02/01/1984 - "We speculated that continuous phosphorus infusion prevents the intermittent hyperphosphatemia of bolus phosphorus supplement and that continuous phosphorus infusion may be useful in the treatment of other hypophosphatemic states of infancy." 12/01/2006 - "Other investigators have noted an association of hyperphosphatemia and LVH; however, this study was the first to demonstrate that improvement in serum phosphorus is associated with reduction in LVM. " 07/01/2009 - "Taken together, these findings suggest that endothelial dysfunction mediated by acute postprandial hyperphosphatemia may contribute to the relationship between serum phosphorus level and the risk for cardiovascular morbidity and mortality." 07/01/2009 - "To determine whether postprandial hyperphosphatemia may promote endothelial dysfunction, we investigated the acute effect of phosphorus loading on endothelial function in vitro and in vivo. " 03/01/2009 - "Salivary phosphorus binding: a novel approach to control hyperphosphatemia." Order ALL the reference details at left...
6.	Calcitriol (Calcijex)FDA LinkGeneric 05/01/2005 - "This study demonstrates that i.v. calcitriol, at initial doses of 0.5-1.5 microg, effectively reduces PTH levels in pediatric HD patients and that patients should be closely monitored for hyperphosphatemia and elevated Ca x P product." 08/01/2000 - "The essence to medical management is to correct the two most important pathogenetic factors of HPT, hyperphosphatemia, and calcitriol deficiency. " 08/01/2000 - "If prevention fails, and even if severe HPT develops, many of these patients can still be controlled medically with correction of hyperphosphatemia and high doses of intravenous calcitriol. " 01/01/2000 - "calcitriol is associated with a lower incidence of hyperphosphatemia and elevated Ca x PO4 byproduct." 01/01/1999 - "Hyperphosphatemia: a serious limiting factor preventing the possible benefit from intravenous calcitriol therapy." Order ALL the reference details at left...
7.	lanthanum carbonate (Fosrenol)FDA Link 01/01/2005 - "Lanthanum carbonate, a new noncalcium, nonaluminum phosphate binder, represents a promising treatment for hyperphosphatemia." 06/01/2003 - "BACKGROUND: Lanthanum carbonate (LC) (Fosrenol) is a novel new treatment for hyperphosphatemia. " 07/01/2009 - "Although data on the safety and efficacy of lanthanum carbonate in the treatment of hyperphosphatemia have been provided in long-term clinical studies, there is still an ongoing scientific debate about its possible long-term toxicity. " 11/01/2008 - "BACKGROUND: The efficacy of lanthanum carbonate as a phosphate binder for the treatment of hyperphosphatemia has been reported, but not from a double-blind, comparator-controlled comparative study. " 07/01/2003 - "Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia." Order ALL the reference details at left...
8.	hydroxide ionIBA 07/01/2009 - "Conversely, decreased FGF-23 activity results in hyperphosphatemia, increased 1,25(OH)(2)D levels, and abnormal soft-tissue calcification. " 12/01/2007 - "1,25(OH)(2)D(3) induces FGF23 78-fold in osteoblasts, and because FGF23 in turn represses 1,25(OH)(2)D(3) synthesis, a reciprocal relationship is established, with FGF23 indirectly curtailing 1,25(OH)(2)D(3)-mediated intestinal absorption and counterbalancing renal reabsorption of phosphate, thereby reversing hyperphosphatemia and preventing ectopic calcification. " 07/01/2007 - "Low FGF23 levels lead to hyperphosphatemia, elevated 1,25(OH)2D, and soft-tissue calcifications. " 04/01/2005 - "Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. " 11/01/2004 - "Fgf-23 null (Fgf-23-/-) mice showed signs of growth retardation by day 17, developed severe hyperphosphatemia with elevated serum 1,25(OH)2D3 levels, and died by 13 weeks of age. " Order ALL the reference details at left...
9.	calcium acetate (Phoslo)FDA LinkGeneric 07/01/2005 - "One of the top 2 common clinical treatments for hyperphosphatemia, calcium acetate, has an established history of efficacy since the 1980s, and has been shown to be cost effective and well tolerated, as well." 08/01/2002 - "A new gelcap form of calcium acetate has been introduced for control of hyperphosphatemia. " 01/01/1991 - "Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia." 12/01/2002 - "Since calcium acetate is the most cost-effective phosphate binder available, we recommend that it should remain the first line treatment of hyperphosphatemia in patients with ESRD." 05/01/2004 - "Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients." Order ALL the reference details at left...
10.	Alkaline PhosphataseIBA 01/01/2005 - "The patients had plasma iPTH levels 8-45 times higher than the top normal limit, high values of alkaline phosphatase, calcemia on the upper normal level, and hyperphosphatemia. " 01/01/1992 - "In contrast, hyperphosphatemia was a constant feature in all the patients, as was the absence of an increase in plasma alkaline phosphatase activity. " 08/01/2009 - "Preoperative symptoms were alleviated, and the serum PTH and alkaline phosphatase levels, hyperphosphatemia, and hypercalcemia were improved or normalized in most patients. " 01/01/2000 - "The groups were compared with regard to changes in serum intact PTH, serum bone-specific alkaline phosphatase (BAP), incidence of hypercalcemia (>10.5 mg/dL), and hyperphosphatemia (>6.5 mg/dL). " 12/01/1999 - "Laboratory investigations revealed hypercalcemia at 12.7 mg/dl, hyperphosphatemia 8.6 mg/dl, and extremely low alkaline phosphatase 0 unit/L. " Order ALL the reference details at left...

Therapies and Procedures

1.	Renal Dialysis (Hemodialysis) 10/01/1999 - "Nocturnal hemodialysis achieves control of hyperphosphatemia without phosphate binders and a significant reduction in serum beta(2)-microglobulin levels. " 06/01/2004 - "This agent appears quite effective in the treatment of hyperphosphatemia in hemodialysis patients, and its usage may be advantageous in the treatment of dialysis patients." 04/01/1999 - "This agent appears quite effective in the treatment of hyperphosphatemia in hemodialysis patients, and its usage may be advantageous in the treatment of dialysis patients." 09/01/1999 - "Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients." 02/01/2009 - "Fermagate showed promising efficacy in the treatment of hyperphosphatemia in chronic hemodialysis patients as compared with placebo in this initial phase II study. " Order ALL the reference details at left...
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD) 05/01/2006 - "The present study was designed to evaluate the efficacy of SH in the control of hyperphosphatemia and its effect, compared to AH, on serum lipid parameters in patients on continuous ambulatory peritoneal dialysis (CAPD). " 04/01/2004 - "CONCLUSION: Hyperphosphatemia is a frequent complication in Chinese CAPD patients. " 01/01/1989 - "Compared to HD the results were as follows: CAPD patients required significantly less aluminium to control hyperphosphatemia (0.16 vs. 0.49 g, p less than 0.005). " 01/01/1988 - "The problem of hypercalcemia and hyperphosphatemia can more easily controlled by CAPD than by hemodialysis. " 01/01/1994 - "We present a continuous ambulatory peritoneal dialysis patient with hypomagnesemia who developed hyperphosphatemia and profound hypocalcemia after oral phosphate replacement for severe hypophosphatemia. " Order ALL the reference details at left...
3.	Protein-Restricted Diet (Diet, Protein Restricted) 08/20/1989 - "For therapy, apart from adequate antihypertensive management, a low-protein diet and treatment of the lipid metabolic disorder and the secondary hyperphosphatemia, is recommended in the patient with chronic renal disease." 01/01/1984 - "According to one hypothesis, hyperphosphatemia (high Ca X P product) is harmful for the diseased kidneys; protein restriction is beneficial, since a low protein diet is generally also low in phosphate. " 07/01/1999 - "However, with the exception of the beneficial effect on hyperphosphatemia of the very low protein diets supplemented with ketoacids, they have no proven effects on the other aspects of the uremic syndrome. " 05/01/1969 - "Reversal of systemic acidosis with oral bicarbonate has resulted in phosphate retention and a rising serum phosphate in one such case.6. Preliminary data from analysis of full-thickness bone biopsy in two osteomalacic patients shows a significant reduction in calcium and phosphate content.7. Despite the hyperphosphatemia of azotemic renal failure, over-all phosphate depletion may be present in this situation also due to: * Diminished dietary phosphate in low protein diets * Nausea and vomiting * Occasional diarrhea * The use of oral phosphatebinding antacids * Perpetuation of urinary phosphate losses by reduction in proportion of tubular reabsorbed phosphate (secondary hyperparathyroidism) and possibly high filtered load per nephron * Repeated losses of phosphate to bath fluid during dialysis." Order ALL the reference details at left...
4.	Adrenalectomy 02/01/1986 - "We found hyperphosphatemia in five patients who had undergone unilateral adrenalectomy (ADX) for resection of cortisol-producing adenomas. " 12/01/1975 - "ACTH was equally effective in inducing hypocalcemia and hyperphosphatemia in the absence of the adrenal glands, while adrenalectomy alone raised plasma calcium. " Order ALL the reference details at left...
5.	Peritoneal Dialysis 04/01/2004 - "This study evaluated significant factors associated with hyperphosphatemia in peritoneal dialysis (PD) patients. " 07/01/2009 - "BACKGROUND: Although hyperphosphatemia is one of the few established risk factors for cardiovascular mortality in patients on dialysis, the relationship between peritoneal dialysis (PD) prescription and dialytic phosphate removal is largely unexplored. " 11/01/2007 - "Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients." 07/01/2005 - "Hyperphosphatemia in children receiving peritoneal dialysis--an educational program." 04/01/2004 - "Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hyperphosphatemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 57 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>